Login / Signup

Re: "A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder" by Strawn et al.-Concerning Harm-Benefit Ratio in a Recent Trial About Escitalopram for Generalized Anxiety Disorder.

Martin PlöderlMark A HorowitzMichael P Hengartner
Published in: Journal of child and adolescent psychopharmacology (2023)
Keyphrases
  • double blind
  • phase iii
  • clinical trial
  • placebo controlled
  • phase ii
  • study protocol
  • major depressive disorder
  • bipolar disorder
  • open label
  • randomized controlled trial
  • cross sectional